A Caltech Library Service

Structure of the Inmazeb cocktail and resistance to Ebola virus escape

Rayaprolu, Vamseedhar and Fulton, Benjamin O. and Rafique, Ashique and Arturo, Emilia and Williams, Dewight and Hariharan, Chitra and Callaway, Heather and Parvate, Amar and Schendel, Sharon L. and Parekh, Diptiben and Hui, Sean and Shaffer, Kelly and Pascal, Kristen E. and Wloga, Elzbieta and Giordano, Stephanie and Negron, Nicole and Ni, Min and Copin, Richard and Atwal, Gurinder S. and Franklin, Matthew and Boytz, Ruth Mabel and Donahue, Callie and Davey, Robert and Baum, Alina and Kyratsous, Christos A. and Saphire, Erica Ollmann (2023) Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host and Microbe, 31 (2). 260-272.e7. ISSN 1931-3128. doi:10.1016/j.chom.2023.01.002.

[img] PDF - Published Version
Creative Commons Attribution Non-commercial No Derivatives.

[img] PDF (Document S1. Figures S1–S6 and Tables S1–S3) - Supplemental Material
Creative Commons Attribution Non-commercial No Derivatives.


Use this Persistent URL to link to this item:


Monoclonal antibodies can provide important pre- or post-exposure protection against infectious disease for those not yet vaccinated or in individuals that fail to mount a protective immune response after vaccination. Inmazeb (REGN-EB3), a three-antibody cocktail against Ebola virus, lessened disease and improved survival in a controlled trial. Here, we present the cryo-EM structure at 3.1 Å of the Ebola virus glycoprotein, determined without symmetry averaging, in a simultaneous complex with the antibodies in the Inmazeb cocktail. This structure allows the modeling of previously disordered portions of the glycoprotein glycan cap, maps the non-overlapping epitopes of Inmazeb, and illuminates the basis for complementary activities and residues critical for resistance to escape by these and other clinically relevant antibodies. We further provide direct evidence that Inmazeb protects against the rapid emergence of escape mutants, whereas monotherapies even against conserved epitopes do not, supporting the benefit of a cocktail versus a monotherapy approach.

Item Type:Article
Related URLs:
URLURL TypeDescription ItemDiscussion Paper
Rayaprolu, Vamseedhar0000-0002-2823-2984
Fulton, Benjamin O.0000-0003-3531-0888
Rafique, Ashique0000-0003-4078-7242
Arturo, Emilia0000-0002-6911-129X
Williams, Dewight0000-0001-8942-8131
Callaway, Heather0000-0003-4003-3854
Parvate, Amar0000-0001-9282-5015
Schendel, Sharon L.0000-0002-5062-7261
Parekh, Diptiben0000-0002-1972-9462
Hui, Sean0000-0002-9870-6823
Shaffer, Kelly0000-0002-6212-1428
Pascal, Kristen E.0000-0003-4826-4606
Wloga, Elzbieta0000-0002-1494-9765
Giordano, Stephanie0000-0001-5879-3275
Copin, Richard0000-0001-7717-2183
Atwal, Gurinder S.0000-0002-0125-6943
Franklin, Matthew0000-0002-1482-0136
Boytz, Ruth Mabel0000-0002-8524-8376
Donahue, Callie0000-0002-4284-2914
Davey, Robert0000-0001-9168-2892
Baum, Alina0000-0001-7179-8679
Kyratsous, Christos A.0000-0002-2596-2906
Saphire, Erica Ollmann0000-0002-1206-7451
Additional Information:Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). We gratefully acknowledge support from NIAID U19 AI142790, the Consortium for Immunotherapeutics against Emerging Viral Threats (E.O.S.), and the U.S. Department of Health and Health Services contract no. HHSO100201700016C (Regeneron). A portion of this project has been funded in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under OT number HHSO100201700020C. GM/CA@APS-23ID-B has been funded by the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006, P30GM138396). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. The Eiger 16M detector at GM/CA-XSD was funded by NIH grant S10 OD012289. Cryo-EM SPA datasets were collected at Arizona State University. We acknowledge the use of facilities within the Eyring Materials Center at Arizona State University supported in part by NNCI-ECCS-1542160. We would like to acknowledge Dr. Dewight Williams from the Eyring Materials Center at Arizona State University supported in part by NNCI-ECCS-1542160 for assisting in data collection. We thank all the staff of the NIH who supported this study, in particular, Kaleb Sharer, Russel Byrum, Jennifer Jackson, Sarah Klim, Danny Ragland, Marisa St Claire, and Lisa Hensley. The authors would like to thank Kristen Tramaglini for her continuous support with this project. Author contributions. Conceptualization, E.O.S., C.A.K., and A.B.; methodology, V.R., B.O.F., A.R., H.C., A.P., K.E.P., R.C., R.D., and E.W.; investigation, V.R., H.C., C.H., B.O.F., A.B., A.R., E.A., K.S., S.H., D.P., E.W., S.G., R.C., K.E.P., R.D., R.M.B., C.D., G.S.A., M.N., and N.N.; formal analysis, V.R., C.H., B.O.F., A.B., A.R., M.F., R.D., and K.E.P.; writing – original draft, V.R., E.O.S., B.O.F., and A.B.; writing – review & editing, V.R., E.O.S., B.O.F., M.F., S.L.S., A.P., C.A.K., and A.B.; visualization, V.R., B.O.F., A.R., and H.C.; supervision, E.O.S., C.A.K., M.F., and A.B.; resources, E.O.S., D.W., C.A.K., A.B., and A.R.; funding acquisition, E.O.S. and C.A.K. Data and code availability. The cryo-EM map has been deposited at the Electron Microscopy Data Bank ( The accession number for the map is EMD-26005. The atomic model corresponding to the microscopy data has been deposited in the Protein Data Bank under the accession number PDB: 7TN9. No custom code was generated as part of the study. Any additional information required to reanalyze the data reported in this work paper is available from the Lead Contact upon request. Declaration of interests. The Regeneron employees have stock and/or options in the company. C.A.K. is an officer of the company. The antibodies are patented: WO/2016/123019. Inclusion and diversity. One or more of the authors of this paper self-identifies as a gender minority in their field of research. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list.
Funding AgencyGrant Number
NIHU19 AI142790
Department of Health and Human ServicesHHSO100201700016C
Department of Health and Human ServicesHHSO100201700020C
Department of Energy (DOE)DE-AC02-06CH11357
NIHS10 OD012289
Issue or Number:2
Record Number:CaltechAUTHORS:20230322-76136000.1
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:120316
Deposited By: George Porter
Deposited On:22 Mar 2023 19:45
Last Modified:22 Mar 2023 19:45

Repository Staff Only: item control page